Is WOCKHARDT LIMITED Halal & Shariah Compliant?
Shariah Screening Verdict
FINANCIAL DATA UPDATE IN PROGRESS ā¢ WOCKPHARMA.NS
Processing financial disclosures
LIVE REFRESH INCOMPLETE ā¢ WOCKPHARMA.NS
Complete audited financial data could not be verified
Stage 1: Business Activity (Sector/Industry level Classification)
Core business activity is screened at the industry level; users are advised to verify company-specific revenue segments.
Stage 2: Financial Ratios
ā¹ļø Shaikhoology's Asset-Based Shariah Screening Methodology & Disclaimer View Hide
Disclaimer: These metrics are provided as a supplementary reference based on available public data. This representation reflects our structured assessment; users are advised to conduct their own independent verification prior to making investment decisions. We do not assume legal or ethical liability for final investment outcomes.
Enter dividend amount
“Wockhardt Limited ā Mukhtasir Jaiza (FY 2025-26 ā Consolidated) 1. Company Kya Kaam Karti Hai? Wockhardt Limited ek global pharmaceutical aur biotech compan...”
“Wockhardt Limited ā Mukhtasir Jaiza (FY 2025-26 ā Consolidated) 1. Company Kya Kaam Karti Hai? Wockhardt Limited ek global pharmaceutical aur biotech company hai. Iska kaam Active Pharmaceutical Ingredients (APIs), branded formulations, biosimilars (insulin, etc.) aur novel antibiotics (NCEs) banana aur bechna hai. Yeh company Antimicrobial Resistance (AMR) ke khilaf duniya ki sabse aage ki antibiotic discovery companies mein se ek hai. Iske paas 6 novel antibiotics hain, jinmein se ZAYNICHĀ® (WCK 5222) ko US FDA approval mila hai ā yeh kisi bhi Indian company ka pehla NCE hai jise US FDA ne approve kiya. Company ka kaam 3 main pillars par based hai: 1. Novel Antibiotics (NCEs) ā AMR ke khilaf breakthrough drugs. 2. Biosimilars (Insulin, etc.) ā Biotech products. 3. Formulations & APIs ā Generic aur branded dawaiyan. 2. Kitne Businesses hain aur unki Income (Segment-wise)? Company ke 2 main reportable segments hain (Note 35 ā Consolidated Financials): Ā· Pharmaceuticals ā yehi ek hi reportable segment hai, kyunki CODM (Chief Operating Decision Maker) poori pharmaceutical business ko ek saath monitor karta hai. Geographical Revenue Breakdown (Consolidated ā Note 35): Region Revenue (ā¹ Crore) Total Revenue mein % UK 1,674 /39% India 740/ 22% Rest of the World (ROW) 958 /28% USA 108/ 3% Europe (EU) ā (included in others) /11% Total Revenue from Operations 3,373 /100% š UK sab se bada market hai (39%), uske baad ROW (28%) aur India (22%). Company ki 78% revenue international se aati hai. Business-wise Revenue (Approximate, based on descriptions): Business Segment Revenue (ā¹ Crore) Total Revenue mein % API Business ~1,600+ ~47% Formulations & Branded ~700+ ~21% Biotech (Biosimilars) ~697 ~21% Novel Antibiotics (NCEs) ~300+ ~9% Others ~100 ~3% Total 3,373 100% ā API sab se bada segment hai, lekin Biotech (697 Cr) aur Novel Antibiotics (300+ Cr) tezi se grow kar rahe hain. 3. Interest Income kitni hai aur Revenue ke % mein? Interest Income (Consolidated ā Note 28): Interest Income ka Source Amount (ā¹ Crore) Interest on bank deposits, loans, etc. 7 Total Interest Income 7 Ā· Total Revenue = ā¹3,373 Crore Ā· Interest Income = ā¹7 Crore Ā· Percentage = (7 / 3,373) Ć 100 = 0.21% š” Interest income total revenue ka 0.21% hai ā bahut kam, kyunki company ka main kaam operations se income generate karna hai, interest se nahi. 4. Kitna Qarz (Debt) hai aur Revenue ke % mein? Total Borrowings (Consolidated ā Note 18 + 22): Qarz ka Type Amount (ā¹ Crore) Non-current Borrowings 1,518 Current Borrowings 607 Total Borrowings 2,125 Ā· Total Revenue = ā¹3,373 Crore Ā· Debt / Revenue % = (2,125 / 3,373) Ć 100 = 63% ā ļø Yeh ratio high hai, lekin company R&D-intensive hai aur isne novel antibiotics mein US$800 million invest kiye hain. Isliye qarz zyada hai, lekin future growth ke liye zaroori hai. --- 5. Qarz (Debt) Assets (Jayedad) ke % mein kitna hai? Ā· Total Borrowings = ā¹2,125 Crore Ā· Total Assets = ā¹7,416 Crore (Consolidated Balance Sheet) Ā· Debt / Assets % = (2,125 / 7,416) Ć 100 = 28.7% ā Assets ke muqaable par qarz 28.7% hai ā jo manageable hai. Pichle saal (FY25) Debt/Assets ā30.5% tha, is saal improvement hua hai. 6. Liquid (Current) aur Illiquid (Non-Current) Assets: Asset Category Amount (ā¹ Crore) Total Assets mein % Liquid Assets (Current Assets) 3,076 /41.5% Illiquid Assets (Non-Current Assets) 4,340 /58.5% Total Assets 7,416 /100% š Illiquid assets (property, plant, intangible assets under development, goodwill) 58.5% hain, kyunki company R&D-intensive hai aur iske paas intangible assets under development (NCEs) ka bada stock hai. Liquid assets (cash, debtors, inventory) 41.5% hain ā jo pharma industry ke hisaab se theek hai. š Khaas Baatein (Summary): Parameter Value Main Business Pharmaceuticals (APIs, Biosimilars, Novel Antibiotics) Biggest Market UK (39%), India (22%), ROW (28%) Interest Income % of Revenue 0.21% Debt / Revenue % 63% (high but R&D-driven) Debt / Assets % 28.7% (safe level) Liquid Assets % 41.5% Illiquid Assets % 58.5% š” Sab se Important Baat: Wockhardt duniya ki un kuch companies mein se hai jinke paas 6 novel antibiotics hain, aur ZAYNICHĀ® ko US FDA approval mil chuka hai ā yeh Indian pharma industry ke liye historic achievement hai. Company AMR (Antimicrobial Resistance) ke khilaf global fight mein leadership position par hai. Iske NCE pipeline (WCK 5222, WCK 4282, WCK 4873, etc.) ka commercialisation aane wale 2-3 saalon mein company ki revenue aur profitability ko bahut zyada badha sakta hai. Isliye current debt ratio high hai, lekin future growth potential bahut strong hai.”
š¬ Community Discussions & Inquiries on WOCKPHARMA.NS 0
No discussions on WOCKPHARMA.NS yet.
Have a question on revenue breakdown, interest income, or compliance? Write your comment below to start the discussion!
Ratio Definitions & Logic
Ratio 1 ā Interest-Bearing Debt / Total Assets
Formula: (Funded Interest-Bearing Debt Ć· Total Assets) Ć 100. Total Debt strictly comprises funded interest-bearing bank borrowings (short-term working capital credit facilities and long-term term loans, credit lines, bonds, debentures, and commercial paper). Operating lease liabilities (Ind AS 116 / Ijarah store, shop, and warehouse rental contracts) are operational usufruct rentals, not Riba-bearing loans, and are strictly excluded from interest-bearing debt per leading national and international Shariah advisory standards. The standard screening threshold limit must be strictly less than 33.00%.
Ratio 2 ā Impermissible Income / Revenue
Formula: (Bank Deposits & FDs + Bonds & Debt Securities + Other Impure Income) Ć· Total Revenue Ć 100. Includes all interest earned by the company (from bank fixed deposits, savings balances, debt instruments, and debentures) along with unpurified non-operating returns inspected directly from financial statement notes to accounts (Note 30 / 35). Pure operational revenue is strictly segregated from non-operating returns. The standard screening threshold limit must be strictly less than or equal to 5.00% per leading national and international Shariah advisory standards.
Ratio 3 ā Liquid Assets / Total Assets
Formula: Total Liquid Assets Ć· Total Assets Ć 100. Total Liquid Assets equals Cash & Bank Balances + Short-Term Current Investments + Trade Receivables (Sundry Debtors). The screening threshold limit must be strictly less than 90.00%.
Sign In to Access Advisor Verdicts & Trend Charts
Unlock verified Shari'ah scholar verdicts, in-depth screening reasoning, curated lists, and multi-quarter financial trend charts with free instant sign in.
Shariah compliance verdicts strictly evaluate official annual audited financial statements filed within 3 years of the current date.
Evaluated on group consolidated financial statements covering the parent entity and all active operating subsidiaries.
Verified Financial Disclosures: Financial figures extracted from available financial disclosures and validated against reporting-period and audit-status requirements.
Dividend Purification Calculator
WOCKPHARMA.NS ā¢ WOCKHARDT LIMITED
Shariah scholars (AAOIFI standards ke tahat) ihtiyat (precaution) ke taur par impure income ka 2x (double) hissa charity mein dene ka mashwara dete hain, taaki bank float, transit interest ya delayed accounting adjustments ka shubha khatam ho sake.
ā ļø Zaroori baat: Is raqam ko bagair sawab ki niyat ke welfare/sadqah mein dena hota hai kyunki iska maqsad sawab nahi balki apne bache hue maalam ko haraam/shubhe se paak karna hai.